Skyline Ventures

Muse Technology is a one-stop online furniture retail and e-commerce platform for the purchase of indoor furniture.

Sutro Biopharma, Inc. is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary integrated cell-free protein synthesis platform known as XpressCF. Sutro Biopharma’s product candidates include STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, an antibody-drug conjugate directed against folate receptor-alpha for treating ovarian and endometrial cancers. The company has also established collaboration and licensing agreements to advance bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, Sutro Biopharma is dedicated to developing innovative biopharmaceutical solutions.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, that specializes in the development and commercialization of implantable devices for surgical treatment of sacropelvic anatomy. Founded in 2008, the company offers a range of patented titanium implants, including the iFuse system, which is designed for the minimally invasive fusion of the sacroiliac joint to alleviate dysfunction that leads to lower back pain. The iFuse implant procedure is noted for its reduced invasiveness and efficiency compared to traditional open fusion methods. In addition to the iFuse system, SI-BONE develops other products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which address various conditions related to sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. The company operates both in the United States and internationally.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, that specializes in the development and commercialization of implantable devices for surgical treatment of sacropelvic anatomy. Founded in 2008, the company offers a range of patented titanium implants, including the iFuse system, which is designed for the minimally invasive fusion of the sacroiliac joint to alleviate dysfunction that leads to lower back pain. The iFuse implant procedure is noted for its reduced invasiveness and efficiency compared to traditional open fusion methods. In addition to the iFuse system, SI-BONE develops other products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which address various conditions related to sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. The company operates both in the United States and internationally.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing products aimed at addressing the challenges associated with pain management and the abuse of prescription drugs. The company utilizes its proprietary DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release and safety profiles of medications, making them less susceptible to misuse through methods such as chewing or injecting. Collegium's primary products include Xtampza ER, an abuse-deterrent extended-release formulation of oxycodone, and Nucynta, which encompasses both extended-release and immediate-release formulations of tapentadol for managing severe pain. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions that enhance patient safety while effectively treating chronic pain conditions.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, that specializes in the development and commercialization of implantable devices for surgical treatment of sacropelvic anatomy. Founded in 2008, the company offers a range of patented titanium implants, including the iFuse system, which is designed for the minimally invasive fusion of the sacroiliac joint to alleviate dysfunction that leads to lower back pain. The iFuse implant procedure is noted for its reduced invasiveness and efficiency compared to traditional open fusion methods. In addition to the iFuse system, SI-BONE develops other products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which address various conditions related to sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. The company operates both in the United States and internationally.

Sutro Biopharma, Inc. is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary integrated cell-free protein synthesis platform known as XpressCF. Sutro Biopharma’s product candidates include STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, an antibody-drug conjugate directed against folate receptor-alpha for treating ovarian and endometrial cancers. The company has also established collaboration and licensing agreements to advance bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, Sutro Biopharma is dedicated to developing innovative biopharmaceutical solutions.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

Crescendo Bioscience, Inc. is a molecular diagnostics company specializing in rheumatology, founded in 2002 and located in South San Francisco, California. The company develops quantitative and objective diagnostic tools aimed at assisting rheumatologists in the management of autoimmune and inflammatory diseases. Its primary product, Vectra DA, is a standardized multi-biomarker blood test designed to assess disease activity in rheumatoid arthritis. This test enables rheumatologists to effectively monitor and manage patients by providing critical disease information and insights. Through its innovative diagnostic and prognostic capabilities, Crescendo Bioscience enhances the decision-making process for therapy selection and patient management.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Sutro Biopharma, Inc. is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary integrated cell-free protein synthesis platform known as XpressCF. Sutro Biopharma’s product candidates include STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, an antibody-drug conjugate directed against folate receptor-alpha for treating ovarian and endometrial cancers. The company has also established collaboration and licensing agreements to advance bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, Sutro Biopharma is dedicated to developing innovative biopharmaceutical solutions.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing products aimed at addressing the challenges associated with pain management and the abuse of prescription drugs. The company utilizes its proprietary DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release and safety profiles of medications, making them less susceptible to misuse through methods such as chewing or injecting. Collegium's primary products include Xtampza ER, an abuse-deterrent extended-release formulation of oxycodone, and Nucynta, which encompasses both extended-release and immediate-release formulations of tapentadol for managing severe pain. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions that enhance patient safety while effectively treating chronic pain conditions.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, that specializes in the development and commercialization of implantable devices for surgical treatment of sacropelvic anatomy. Founded in 2008, the company offers a range of patented titanium implants, including the iFuse system, which is designed for the minimally invasive fusion of the sacroiliac joint to alleviate dysfunction that leads to lower back pain. The iFuse implant procedure is noted for its reduced invasiveness and efficiency compared to traditional open fusion methods. In addition to the iFuse system, SI-BONE develops other products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which address various conditions related to sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. The company operates both in the United States and internationally.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Talphera is a specialty pharmaceutical company dedicated to developing and commercializing therapies tailored for medically supervised environments. The company offers innovative products such as NanoTab, designed for oral transmucosal administration, and the Sufentanil NanoTab PCA system, which is a sublingual patient-controlled analgesia system aimed at managing acute postoperative pain in hospital settings. Additionally, Talphera provides Sufentanil NanoTab BTP management systems for cancer pain treatment and Sufentanil/Triazolam NanoTab, which delivers both analgesia and sedation for minor outpatient procedures. The company's diverse portfolio also includes nafamostat product candidates and pre-filled syringe product candidates, reflecting its commitment to addressing critical pain management needs.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Sutro Biopharma, Inc. is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary integrated cell-free protein synthesis platform known as XpressCF. Sutro Biopharma’s product candidates include STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, an antibody-drug conjugate directed against folate receptor-alpha for treating ovarian and endometrial cancers. The company has also established collaboration and licensing agreements to advance bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, Sutro Biopharma is dedicated to developing innovative biopharmaceutical solutions.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, that specializes in the development and commercialization of implantable devices for surgical treatment of sacropelvic anatomy. Founded in 2008, the company offers a range of patented titanium implants, including the iFuse system, which is designed for the minimally invasive fusion of the sacroiliac joint to alleviate dysfunction that leads to lower back pain. The iFuse implant procedure is noted for its reduced invasiveness and efficiency compared to traditional open fusion methods. In addition to the iFuse system, SI-BONE develops other products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which address various conditions related to sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. The company operates both in the United States and internationally.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Calypso Medical Technologies is a Seattle-based medical device company that specializes in real-time localization technology for tumor tracking. Its proprietary system employs miniaturized implanted devices, known as Beacon electromagnetic transponders, to continuously and accurately monitor the location of tumors. This innovative approach aims to enhance the precision and management of radiation therapy delivery, particularly for body-wide cancers commonly treated with this method. The company's products have received FDA 510(k) clearance for use in the prostate and post-operative prostatic bed. Calypso Medical has established strategic partnerships with major industry players, including Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

SpinalMotion is a private company focused on preserving spinal motion for patients suffering from degenerative disc disease. Founded in 2004, the company specializes in the development of innovative artificial disc implants that utilize proprietary Kineflex Technology, designed to maintain the natural movement of the spine while offering low wear and improved longevity. Since obtaining FDA approval in 2005 to conduct clinical trials for lumbar and cervical artificial discs in the United States, SpinalMotion has built on its international clinical experience to enhance patient outcomes. The company has attracted investment from notable partners, including Southern Medical, Three Arch Partners, Skyline Ventures, and MedVenture Associates, to further its mission of enabling patients to lead pain-free and healthy lives.

Mako Surgical is a medical device company based in Florida, specializing in advanced robotic arm solutions and orthopedic implants for minimally invasive procedures, particularly in knee and hip surgeries. The company’s flagship offering, MAKOplasty, is a restorative surgical solution designed to assist orthopedic surgeons in treating early to mid-stage osteoarthritic conditions in patients. Mako Surgical's robotic arm interactive orthopedic system (RIO) features a tactile robotic arm and an integrated bone cutting instrument, providing pre-operative and intra-operative guidance to enhance surgical precision. This technology facilitates tissue-sparing bone removal and accurate implant insertion and alignment, ultimately improving patient outcomes. Founded in 2004, Mako Surgical has gained recognition in the medical technology field, having been named the fastest growing technology company by Deloitte and receiving multiple awards for customer excellence and innovation.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

InteKrin Therapeutics is a clinical-stage, privately held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for neuroendocrine, metabolic, and immune disorders. The company is focused on addressing critical healthcare challenges, particularly in diseases such as diabetes, metabolic syndrome, and cancer, which require new treatment options to improve patient outcomes and reduce healthcare costs. InteKrin is actively in-licensing both early- and late-stage compounds aimed at exploring the intricate hormonal relationships influencing metabolism, insulin resistance, and obesity. Among its key developments is INT131, a non-TZD peroxisome proliferator-activated receptor gamma modulator designed to treat Relapsing Remitting Multiple Sclerosis, which seeks to provide neuroprotection while halting the progression of this serious condition.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

NovaSys Health is a prominent provider of managed healthcare services, operating one of the largest health plans in Arkansas. With approximately 11,000 contracted providers in the region and over 4,300 in Arkansas, the company emphasizes strong relationships with healthcare providers. It offers a range of health plans and related services, including customized solutions, provider relations, and eligibility and billing administration, catering to a diverse network of hospitals, physicians, and ancillary providers.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drugs to treat autoimmune and central nervous system disorders. The company employs a unique precision deuterium chemistry platform to modify the properties of validated drug molecules, resulting in a diverse pipeline of new chemical entities. Key product candidates include CTP-543, which is in Phase III trials for alopecia areata, and CTP-692, undergoing Phase II trials for schizophrenia. Additionally, AVP-786, a combination therapy for neurologic and psychiatric disorders, is also in Phase III trials. Concert Pharmaceuticals aims to enhance drug safety and efficacy while minimizing research and development risks and costs. Established in 2006 and based in Lexington, Massachusetts, the company has formed strategic collaborations with several pharmaceutical partners to advance its innovative drug development efforts.

Sequel Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes novel and clinical-stage drug candidates for patients with cardiovascular disease. The company was founded in 2007 and is based in San Diego, California.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Medivance, Inc. specializes in the development, manufacturing, and distribution of temperature management products for hospitals globally. Founded in 1998 and headquartered in Louisville, Colorado, with an additional office in The Hague, the Netherlands, the company is known for its flagship product, the Arctic Sun Temperature Management System. This innovative system enables clinicians to noninvasively manage and monitor patient temperature, enhancing therapeutic outcomes. In addition to its product offerings, Medivance provides clinical training in Targeted Temperature Management to ensure effective application in medical settings. As of November 2011, Medivance operates as a subsidiary of Bard Medical, Inc.

Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety, Inc. was founded in 2000 through a collaboration of medical device incubators Thomas Fogarty Engineering and The Foundry, and is headquartered in Palo Alto, California.

ARCA biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. ARCA’s principal focus is to develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development.

NovaCardia is a pharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of novel small molecule drugs. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia leverages its extensive expertise in cardiovascular drug development to address critical needs in this therapeutic area.

Eurofins DiscoverX Products is a biotechnology company that develops, manufactures, and commercializes reagents and assay kits for drug discovery, screening, and life science markets. The company specializes in providing validated assays for various drug targets such as GPCRs, kinases, and proteases, among others. Its offerings include pre-validated cell lines, assay ready kits, biochemical assays, and detection reagents. Additionally, Eurofins DiscoverX Products provides custom assay development services and serves pharmaceutical, biotechnology, and academic laboratories worldwide. The company operates as a subsidiary of Eurofins Scientific SE, with offices in Fremont, San Diego, San Francisco, California, and Birmingham, United Kingdom.

Map Pharmaceuticals, Inc. is a development stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, which targets migraine relief. Additionally, the product portfolio features MAP0005 for the treatment of asthma and chronic obstructive pulmonary disease in adolescents and adults, as well as MAP0001, designed for pulmonary delivery of medications for Type 1 and Type 2 diabetes utilizing the Tempo inhaler. Map Pharmaceuticals is focused on improving treatment options for patients with various health conditions.

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drugs to treat autoimmune and central nervous system disorders. The company employs a unique precision deuterium chemistry platform to modify the properties of validated drug molecules, resulting in a diverse pipeline of new chemical entities. Key product candidates include CTP-543, which is in Phase III trials for alopecia areata, and CTP-692, undergoing Phase II trials for schizophrenia. Additionally, AVP-786, a combination therapy for neurologic and psychiatric disorders, is also in Phase III trials. Concert Pharmaceuticals aims to enhance drug safety and efficacy while minimizing research and development risks and costs. Established in 2006 and based in Lexington, Massachusetts, the company has formed strategic collaborations with several pharmaceutical partners to advance its innovative drug development efforts.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

NovaCardia is a pharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of novel small molecule drugs. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia leverages its extensive expertise in cardiovascular drug development to address critical needs in this therapeutic area.

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drugs to treat autoimmune and central nervous system disorders. The company employs a unique precision deuterium chemistry platform to modify the properties of validated drug molecules, resulting in a diverse pipeline of new chemical entities. Key product candidates include CTP-543, which is in Phase III trials for alopecia areata, and CTP-692, undergoing Phase II trials for schizophrenia. Additionally, AVP-786, a combination therapy for neurologic and psychiatric disorders, is also in Phase III trials. Concert Pharmaceuticals aims to enhance drug safety and efficacy while minimizing research and development risks and costs. Established in 2006 and based in Lexington, Massachusetts, the company has formed strategic collaborations with several pharmaceutical partners to advance its innovative drug development efforts.

Avidia, Inc. is a biopharmaceutical company based in Mountain View, California, that specializes in discovering and developing therapeutic proteins. Founded in 2003, the company focuses on creating Avimer therapeutic proteins designed to treat a range of medical conditions, including autoimmunity, inflammation, oncology, and neurology. Avidia employs innovative protein structural motifs to address these therapeutic areas, aiming to provide effective treatment options for various ailments.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

KAI Pharmaceuticals is a drug discovery and development company focused on creating innovative therapeutics for cardiovascular disease, kidney disease, and pain management. The company's lead product candidate, KAI-9803, is undergoing a Phase 2b clinical trial aimed at evaluating its ability to reduce myocardial injury in patients experiencing heart attacks. Additionally, KAI is advancing its second core program, KAI-4169, which targets secondary hyperparathyroidism in kidney disease patients and is anticipated to enter human clinical trials. The company is also exploring pain management through its ongoing program, KAI-1678, currently in Phase 2a testing.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Map Pharmaceuticals, Inc. is a development stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, which targets migraine relief. Additionally, the product portfolio features MAP0005 for the treatment of asthma and chronic obstructive pulmonary disease in adolescents and adults, as well as MAP0001, designed for pulmonary delivery of medications for Type 1 and Type 2 diabetes utilizing the Tempo inhaler. Map Pharmaceuticals is focused on improving treatment options for patients with various health conditions.

Hansen Medical, Inc. specializes in the development, manufacture, and sale of medical robotics aimed at enhancing the positioning, manipulation, and control of catheters and catheter-based technologies. The company offers the Sensei systems and Artisan Control Catheters, which are used in electrophysiology procedures to improve catheter navigation and control. Additionally, Hansen Medical provides the CoHesion 3D Visualization Module, a software tool that enhances physicians' ability to visualize catheter placement in three dimensions. Another key product is the Magellan Robotic System, which facilitates remote navigation and vessel cannulation using a telescoping, robotically steerable catheter. The company markets and supports its products through a combination of direct sales, distributors, and sales representatives. Founded in 2002 and headquartered in Mountain View, California, Hansen Medical operates as a subsidiary of Auris Surgical Robotics, Inc. since July 2016.

Guava Technologies, Inc. is a biotechnology and medical device manufacturer based in Hayward, California. Founded in 1998, the company specializes in the development, design, and manufacturing of products used primarily in cell biology research and clinical diagnostics. Its offerings include a range of assays for monitoring HIV/AIDS, cell counting, antibody quantification, cytotoxicity, and apoptosis, as well as benchtop cell analysis systems. Guava Technologies also produces flow cytometry systems tailored for various applications in life science research and drug discovery. As of 2009, Guava Technologies operates as a subsidiary of Millipore Corp.

iBalance Medical, Inc is a privately held medical device company located in Boulder, Colorado. Their focus is in advancing principles and surgical methods for the treatment of joint malalignment. Their initial development centers on providing a reproducible and predictable solution for knee malalignment.

Receptor BioLogix is a biotechnology company based in Palo Alto, California, focused on developing receptor-based biological therapeutics aimed at treating cancer, inflammatory, and autoimmune diseases. The company specializes in creating Hermodulins, which are pan-HER ligand traps designed to inhibit the compensatory feedback mechanisms that can reduce the effectiveness and longevity of various cancer treatments. Additionally, Receptor BioLogix utilizes its Intron Fusion Protein platform to discover novel splice variants of human proteins, which hold therapeutic potential. Through these innovative approaches, the company aims to enhance treatment options and improve outcomes for patients with challenging medical conditions.

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Map Pharmaceuticals, Inc. is a development stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, which targets migraine relief. Additionally, the product portfolio features MAP0005 for the treatment of asthma and chronic obstructive pulmonary disease in adolescents and adults, as well as MAP0001, designed for pulmonary delivery of medications for Type 1 and Type 2 diabetes utilizing the Tempo inhaler. Map Pharmaceuticals is focused on improving treatment options for patients with various health conditions.

KAI Pharmaceuticals is a drug discovery and development company focused on creating innovative therapeutics for cardiovascular disease, kidney disease, and pain management. The company's lead product candidate, KAI-9803, is undergoing a Phase 2b clinical trial aimed at evaluating its ability to reduce myocardial injury in patients experiencing heart attacks. Additionally, KAI is advancing its second core program, KAI-4169, which targets secondary hyperparathyroidism in kidney disease patients and is anticipated to enter human clinical trials. The company is also exploring pain management through its ongoing program, KAI-1678, currently in Phase 2a testing.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.

Roche NimbleGen is a biotechnology company headquartered in Madison, Wisconsin, that specializes in providing products and services for the life science research market. The company offers a range of solutions including the SeqCap EZ system, which enhances exome enrichment in a single test tube, as well as various library construction kits and reagents. Roche NimbleGen's SeqCap Epi system focuses on DNA methylation assessment, providing tools for single-base resolution analysis. The company utilizes its proprietary Maskless Array Synthesis technology to manufacture high-density DNA microarrays, improving the quality and yield of DNA sequencing data. Additionally, Roche NimbleGen offers software tools such as SignalMap for genomic data visualization and NimbleDesign for library design, alongside comprehensive online technical support. Established in 1999, Roche NimbleGen operates as a subsidiary of Roche Holding AG, emphasizing research and innovation in genomic technologies.

Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.

Advion is a global company founded in 1993 and headquartered in New York, specializing in systems and consumables for life science research. It provides a range of biochemistry analysis equipment, including microfluidic devices and mass spectrometry products aimed at supporting various sectors such as biopharmaceuticals, academic and government research, and industrial chemistry. Advion’s offerings include purpose-built mass spectrometers, nanoelectrospray ionization sources, and flow-chemistry synthesis systems, catering to the needs of pharmaceutical companies, research agencies, and universities worldwide.

Renovis, Inc. is a biopharmaceutical company focused on developing innovative drugs for neurological diseases and disorders. The company is actively engaged in creating treatments for acute ischemic stroke, neuropathic pain, and acute post-operative pain. Utilizing advanced techniques in molecular biology, medicinal chemistry, and pharmacology, Renovis identifies and selects small molecule drug candidates that adhere to rigorous development standards. Through a combination of in vitro and in vivo studies, drug metabolism and pharmacokinetics assessments, and toxicological evaluations, Renovis aims to deliver effective therapeutic solutions to address significant unmet medical needs in neurology.

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

Roche NimbleGen is a biotechnology company headquartered in Madison, Wisconsin, that specializes in providing products and services for the life science research market. The company offers a range of solutions including the SeqCap EZ system, which enhances exome enrichment in a single test tube, as well as various library construction kits and reagents. Roche NimbleGen's SeqCap Epi system focuses on DNA methylation assessment, providing tools for single-base resolution analysis. The company utilizes its proprietary Maskless Array Synthesis technology to manufacture high-density DNA microarrays, improving the quality and yield of DNA sequencing data. Additionally, Roche NimbleGen offers software tools such as SignalMap for genomic data visualization and NimbleDesign for library design, alongside comprehensive online technical support. Established in 1999, Roche NimbleGen operates as a subsidiary of Roche Holding AG, emphasizing research and innovation in genomic technologies.

Guava Technologies, Inc. is a biotechnology and medical device manufacturer based in Hayward, California. Founded in 1998, the company specializes in the development, design, and manufacturing of products used primarily in cell biology research and clinical diagnostics. Its offerings include a range of assays for monitoring HIV/AIDS, cell counting, antibody quantification, cytotoxicity, and apoptosis, as well as benchtop cell analysis systems. Guava Technologies also produces flow cytometry systems tailored for various applications in life science research and drug discovery. As of 2009, Guava Technologies operates as a subsidiary of Millipore Corp.

Medivance, Inc. specializes in the development, manufacturing, and distribution of temperature management products for hospitals globally. Founded in 1998 and headquartered in Louisville, Colorado, with an additional office in The Hague, the Netherlands, the company is known for its flagship product, the Arctic Sun Temperature Management System. This innovative system enables clinicians to noninvasively manage and monitor patient temperature, enhancing therapeutic outcomes. In addition to its product offerings, Medivance provides clinical training in Targeted Temperature Management to ensure effective application in medical settings. As of November 2011, Medivance operates as a subsidiary of Bard Medical, Inc.

iScribe is a healthcare technology company that is focused on the development of mobile, handheld, and wireless electronic prescribing technology solutions. iScribe was founded by David Levison in 1999.

XenoPort, Inc. is a biopharmaceutical company based in Santa Clara, California, that specializes in the development and commercialization of a portfolio of product candidates aimed at treating neurological and other disorders. The company markets HORIZANT (gabapentin enacarbil) extended-release tablets in the United States for moderate-to-severe primary restless legs syndrome and postherpetic neuralgia in adults. Its pipeline includes XP23829, a fumaric acid ester compound in Phase III trials for psoriasis and relapsing forms of multiple sclerosis, and arbaclofen placarbil, currently in Phase II trials for spasticity in multiple sclerosis. Additionally, XP21279, aimed at treating advanced idiopathic Parkinson's disease, has completed Phase II trials. XenoPort has secured licensing and collaboration agreements with various pharmaceutical companies to further develop its products. Founded in 1999, XenoPort became a subsidiary of Arbor Pharmaceuticals, LLC in July 2016.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate, vecabrutinib, is a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK) currently undergoing Phase 1b/2 clinical trials for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. Additionally, Sunesis is advancing SNS-510, which is in preclinical studies for various tumor types, alongside partnered programs such as TAK-580, a pan-Raf inhibitor in Phase 1 trials for pediatric low-grade glioma, and vosaroxin, an anti-cancer quinolone derivative. The company has established collaborations, including an agreement with Biogen Idec MA, Inc. for small molecule BTK inhibitors and a licensing agreement with Takeda Pharmaceutical Company Limited for preclinical PDK1 inhibitors. Founded in 1998 and headquartered in South San Francisco, California, Sunesis Pharmaceuticals is committed to innovative approaches in the ongoing fight against cancer.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate, vecabrutinib, is a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK) currently undergoing Phase 1b/2 clinical trials for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. Additionally, Sunesis is advancing SNS-510, which is in preclinical studies for various tumor types, alongside partnered programs such as TAK-580, a pan-Raf inhibitor in Phase 1 trials for pediatric low-grade glioma, and vosaroxin, an anti-cancer quinolone derivative. The company has established collaborations, including an agreement with Biogen Idec MA, Inc. for small molecule BTK inhibitors and a licensing agreement with Takeda Pharmaceutical Company Limited for preclinical PDK1 inhibitors. Founded in 1998 and headquartered in South San Francisco, California, Sunesis Pharmaceuticals is committed to innovative approaches in the ongoing fight against cancer.